535 related articles for article (PubMed ID: 28720112)
1. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
[TBL] [Abstract][Full Text] [Related]
2. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study.
Zou CX; Becker JE; Phillips AT; Garritano JM; Krumholz HM; Miller JE; Ross JS
Trials; 2018 Oct; 19(1):581. PubMed ID: 30352601
[TBL] [Abstract][Full Text] [Related]
3. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA.
Swanson MJ; Johnston JL; Ross JS
Trials; 2021 Nov; 22(1):817. PubMed ID: 34789308
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012.
Miller JE; Korn D; Ross JS
BMJ Open; 2015 Nov; 5(11):e009758. PubMed ID: 26563214
[TBL] [Abstract][Full Text] [Related]
5. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies.
Miller JE; Wilenzick M; Ritcey N; Ross JS; Mello MM
BMJ Open; 2017 Dec; 7(12):e017917. PubMed ID: 29208616
[TBL] [Abstract][Full Text] [Related]
6. Clinical trial transparency: a reassessment of industry compliance with clinical trial registration and reporting requirements in the United States.
Lassman SM; Shopshear OM; Jazic I; Ulrich J; Francer J
BMJ Open; 2017 Sep; 7(9):e015110. PubMed ID: 28942418
[TBL] [Abstract][Full Text] [Related]
7. Evaluating publication bias for clinical trials supporting new dermatologic drug approvals from 2003 to 2018.
Ravichandran S; Mulligan KM; Ezaldein HH; Scott JF
Arch Dermatol Res; 2023 May; 315(4):831-838. PubMed ID: 36333459
[TBL] [Abstract][Full Text] [Related]
8. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
Vaduganathan M; Butler J; Gheorghiade M
Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
[No Abstract] [Full Text] [Related]
9. Publication of clinical trials supporting successful new drug applications: a literature analysis.
Lee K; Bacchetti P; Sim I
PLoS Med; 2008 Sep; 5(9):e191. PubMed ID: 18816163
[TBL] [Abstract][Full Text] [Related]
10. [Regulations concerning data transparency- a comparison between the USA and Europe].
Quack C
Z Evid Fortbild Qual Gesundhwes; 2011; 105(3):183-8. PubMed ID: 21530907
[TBL] [Abstract][Full Text] [Related]
11. Compliance with results reporting at ClinicalTrials.gov.
Anderson ML; Chiswell K; Peterson ED; Tasneem A; Topping J; Califf RM
N Engl J Med; 2015 Mar; 372(11):1031-9. PubMed ID: 25760355
[TBL] [Abstract][Full Text] [Related]
12. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.
DeVito NJ; Bacon S; Goldacre B
Lancet; 2020 Feb; 395(10221):361-369. PubMed ID: 31958402
[TBL] [Abstract][Full Text] [Related]
13. FDA given new powers over data reporting to national clinical trials registry.
Roehr B
BMJ; 2012 Oct; 345():e6629. PubMed ID: 23033375
[No Abstract] [Full Text] [Related]
14. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.
Wallach JD; Egilman AC; Dhruva SS; McCarthy ME; Miller JE; Woloshin S; Schwartz LM; Ross JS
BMJ; 2018 May; 361():k2031. PubMed ID: 29794072
[TBL] [Abstract][Full Text] [Related]
15. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.
Wallach JD; Luxkaranayagam AT; Dhruva SS; Miller JE; Ross JS
BMC Med; 2019 Jun; 17(1):117. PubMed ID: 31203816
[TBL] [Abstract][Full Text] [Related]
16. Public availability of results of trials assessing cancer drugs in the United States.
Nguyen TA; Dechartres A; Belgherbi S; Ravaud P
J Clin Oncol; 2013 Aug; 31(24):2998-3003. PubMed ID: 23878298
[TBL] [Abstract][Full Text] [Related]
17. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
[TBL] [Abstract][Full Text] [Related]
18. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA.
Talebi R; Redberg RF; Ross JS
Trials; 2020 Jul; 21(1):675. PubMed ID: 32703252
[TBL] [Abstract][Full Text] [Related]
19. Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.
Withycombe B; Ovenell M; Meeker A; Ahmed SM; Hartung DM
J Clin Epidemiol; 2016 Sep; 77():78-83. PubMed ID: 27108488
[TBL] [Abstract][Full Text] [Related]
20. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles.
Pranić S; Marušić A
J Clin Epidemiol; 2016 Feb; 70():26-37. PubMed ID: 26226103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
